Skip to main content
BSEM
NASDAQ Life Sciences

BioStem Q2 Revenue Jumps 29% Sequentially; Raises Full-Year Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.8
Mkt Cap
$67.765M
52W Low
$3.01
52W High
$10.71
52W Position info
26% above low
Off High info
65% below high
Rel. Volume info
2.7× avg
Market data snapshot near publication time

BSEM sits 26% above its 52-week low of $3.01 on elevated volume (2.7× avg).

Summary

BioStem Technologies reported strong Q2 revenue growth of 29% sequentially and raised its full-year guidance, but continues to burn cash with a $9.0 million net loss.


Key Events · Earnings and Guidance · BSEM

  • Q2 Revenue Up 29% Sequentially

    Net revenue reached $7.9 million in Q2 2026, up from $6.1 million in Q1 2026, driven by Neox and Clarix product sales.

  • Full-Year Guidance Raised

    Company now expects full-year 2026 revenue of $26-$29 million, up from prior guidance of $25-$29 million.

  • GAAP Net Loss of $9.0M

    Q2 2026 net loss was $9.0 million, or $0.52 per share, compared to a $10,613 net income in Q2 2025.

  • Cash Burn Continues

    Cash used in operations was $5.5 million in Q2, reducing cash to $7.0 million as of June 30, 2026, from $13.7 million at end of Q1.


Analysis · BSEM · Life Sciences

BioStem reported Q2 revenue of $7.9 million, up 29% from Q1, and raised its full-year 2026 revenue guidance to $26-$29 million. The company also disclosed a $9.0 million GAAP net loss and cash burn of $5.5 million, leaving $7.0 million in cash. The revenue growth and guidance raise are positive, but the ongoing losses and cash consumption remain a concern, especially with a $10 million payment obligation due by September 15, 2026.

How filings like this one have moved

In the 30 days to Oct 3, 2026, 36.6% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BSEM was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.8M. The 52-week trading range was $3.01 to $10.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BSEM - Latest Insights

BSEM
Sep 30, 2026, 4:48 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.09
Real-time Price: $2.74 info
Change: -$0.3501 (-11%) info
Market Cap: $48.684M info
BSEM
Sep 29, 2026, 4:56 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $3.83
Real-time Price: $2.74 info
Change: -$1.09 (-28%) info
Market Cap: $48.684M info
BSEM
Sep 18, 2026, 5:24 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $4.74
Real-time Price: $2.74 info
Change: -$2.00 (-42%) info
Market Cap: $48.684M info
BSEM
Sep 18, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.74
Real-time Price: $2.74 info
Change: -$2.00 (-42%) info
Market Cap: $48.684M info
BSEM
Aug 12, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $2.74 info
Change: -$1.06 (-28%) info
Market Cap: $48.684M info